Evaluating Antigen- and Vector-Specific Immune Responses of a Recombinant Pichinde Virus-Based Vaccine Expressing the Lymphocytic Choriomeningitis Virus Nucleoprotein

Overview

Journal Vaccines (Basel)

Date 2025 Jan 8

PMID 39772112

Authors

Michaela Cain

Qinfeng Huang

Shania Sanchez

Hinh Ly

Yuying Liang

Affiliations

Soon will be listed here.

Abstract

Background: Live viral vector-based vaccines are known to elicit strong immune responses, but their use can be limited by anti-vector immunity. Here, we analyzed the immunological responses of a live-attenuated recombinant Pichinde virus (PICV) vector platform (rP18tri).

Methods: To evaluate anti-PICV immunity in the development of vaccine antigen-specific immune responses, we generated a rP18tri-based vaccine expressing the lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP) and administered four doses of this rP18tri-NPLCMV vaccine to mice. Using MHC-I tetramers to detect PICV NP38-45 and LCMV NP396-404 epitope-specific CD8+ T cells, we monitored vector- and vaccine-antigen-specific immune responses after each vaccination dose.

Results: LCMV NP396-404-specific effector and memory CD8+ T cells were detected after the first dose and peaked after the second dose, whereas PICV NP38-45-specific memory CD8+ T cells increased with each dose. PICV-binding IgG antibodies peaked after the second dose, while anti-PICV neutralizing antibodies (NAbs) remained low even after the fourth dose. Immunization with the rP18tri-NPLCMV vaccine significantly reduced LCMV viral titers in a chronic LCMV Clone 13 infection model, demonstrating the protective role of LCMV NP-specific T cells.

Conclusion: These findings provide important insights into the antigen- and vector-specific immunity of the rP18tri-NPLCMV vaccine and support the development of NP-based vaccines against arenavirus pathogens.

References

Schwendinger M, Thiry G, De Vos B, Leroux-Roels G, Bruhwyler J, Huygens A . A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. J Infect Dis. 2020; 225(8):1399-1410. PMC: 9016443. DOI: 10.1093/infdis/jiaa121. View

Flatz L, Cheng C, Wang L, Foulds K, Ko S, Kong W . Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol. 2012; 86(15):7760-70. PMC: 3421661. DOI: 10.1128/JVI.00599-12. View

Dhanwani R, Ly H, Liang Y . Recombinant Tri-Segmented Pichinde Virus as a Novel Live Viral Vaccine Platform. Methods Mol Biol. 2017; 1581:169-179. PMC: 6340294. DOI: 10.1007/978-1-4939-6869-5_10. View

Althaus C, Ganusov V, De Boer R . Dynamics of CD8+ T cell responses during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol. 2007; 179(5):2944-51. DOI: 10.4049/jimmunol.179.5.2944. View

LaVergne S, Sakabe S, Momoh M, Kanneh L, Bond N, Garry R . Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors. PLoS Negl Trop Dis. 2022; 16(11):e0010882. PMC: 9731491. DOI: 10.1371/journal.pntd.0010882. View

Kotturi M, Botten J, Maybeno M, Sidney J, Glenn J, Bui H . Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage. Immunome Res. 2010; 6:4. PMC: 2880318. DOI: 10.1186/1745-7580-6-4. View

Pinschewer D, Perez M, de la Torre J . Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol. 2003; 77(6):3882-7. PMC: 149515. DOI: 10.1128/jvi.77.6.3882-3887.2003. View

Travieso T, Li J, Mahesh S, Mello J, Blasi M . The use of viral vectors in vaccine development. NPJ Vaccines. 2022; 7(1):75. PMC: 9253346. DOI: 10.1038/s41541-022-00503-y. View

Saito T, Reyna R, Taniguchi S, Littlefield K, Paessler S, Maruyama J . Vaccine Candidates against Arenavirus Infections. Vaccines (Basel). 2023; 11(3). PMC: 10057967. DOI: 10.3390/vaccines11030635. View

10.

Snell L, Macleod B, Law J, Osokine I, Elsaesser H, Hezaveh K . CD8 T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity. Immunity. 2018; 49(4):678-694.e5. PMC: 8060917. DOI: 10.1016/j.immuni.2018.08.002. View

11.

Dhanwani R, Zhou Y, Huang Q, Verma V, Dileepan M, Ly H . A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose. J Virol. 2015; 90(5):2551-60. PMC: 4810697. DOI: 10.1128/JVI.02705-15. View

12.

Draper S, Heeney J . Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2009; 8(1):62-73. DOI: 10.1038/nrmicro2240. View

13.

Sommerstein R, Flatz L, Remy M, Malinge P, Magistrelli G, Fischer N . Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog. 2015; 11(11):e1005276. PMC: 4654586. DOI: 10.1371/journal.ppat.1005276. View

14.

Altenburg A, van Trierum S, de Bruin E, de Meulder D, van de Sandt C, van der Klis F . Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. Sci Rep. 2018; 8(1):6474. PMC: 5915537. DOI: 10.1038/s41598-018-24820-2. View

15.

Lan S, McLay Schelde L, Wang J, Kumar N, Ly H, Liang Y . Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J Virol. 2009; 83(13):6357-62. PMC: 2698569. DOI: 10.1128/JVI.00019-09. View

16.

Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y . Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023; 8(1):149. PMC: 10081433. DOI: 10.1038/s41392-023-01408-5. View

17.

Grusdat M, Dostert C, Brenner D . Quantification of lymphocytic choriomeningitis virus specific T cells and LCMV viral titers. Methods Cell Biol. 2023; 173:121-131. DOI: 10.1016/bs.mcb.2022.03.003. View

18.

Kumar P, Sharafeldin T, Kumar R, Huang Q, Liang Y, Goyal S . Development of a Recombinant Pichinde Virus-Vectored Vaccine against Turkey Arthritis Reovirus and Its Immunological Response Characterization in Vaccinated Animals. Pathogens. 2021; 10(2). PMC: 7918942. DOI: 10.3390/pathogens10020197. View

19.

Deng S, Liang H, Chen P, Li Y, Li Z, Fan S . Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms. 2022; 10(7). PMC: 9317404. DOI: 10.3390/microorganisms10071450. View

20.

Sakabe S, Hartnett J, Ngo N, Goba A, Momoh M, Sandi J . Identification of Common CD8 T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone. J Virol. 2020; 94(12). PMC: 7307091. DOI: 10.1128/JVI.00153-20. View